S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.11%) $0.928
USD/NOK
(0.27%) $10.87
USD/GBP
(0.01%) $0.792
USD/RUB
(-0.03%) $92.55

Realtime updates for ImmunoGen Inc [IMGN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 7.25%
SELL
25.00%
return 0.71%
Last Updated9 Feb 2024 @ 15:58

0.02% $ 31.24

SELL 71284 min ago

@ $31.23

Issued: 8 Feb 2024 @ 09:30


Return: 0.02%


Previous signal: Feb 7 - 15:55


Previous signal: Buy


Return: 5.67 %

Live Chart Being Loaded With Signals

Commentary (9 Feb 2024 @ 15:58):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm...

Stats
Today's Volume 19.31M
Average Volume 8.29M
Market Cap 8.73B
EPS $0 ( 2024-03-06 )
Next earnings date ( $0 ) 2024-04-26
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -111.55
ATR14 $0.306 (0.98%)
Insider Trading
Date Person Action Amount type
2024-02-12 Mitchell Dean J Sell 103 000 Common Stock
2024-02-12 Mitchell Dean J Sell 13 090 Restricted Stock Unit
2024-02-12 Mitchell Dean J Sell 142 667 Deferred Share Unit
2024-02-12 Mitchell Dean J Sell 10 000 Stock Option (Right to Buy)
2024-02-12 Mitchell Dean J Sell 10 000 Stock Option (Right to Buy)
INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 | Sell: 8 781 240

Volume Correlation

Long: 0.24 (neutral)
Short: 0.25 (neutral)
Signal:(82.516) Neutral

ImmunoGen Inc Correlation

10 Most Positive Correlations
HOL0.945
IRBT0.93
SLNG0.929
RTPY0.927
KBSF0.926
LGMK0.92
RPID0.919
FIBK0.917
GBCI0.917
LYEL0.917
10 Most Negative Correlations
AEAE-0.941
ENTF-0.941
CCTS-0.941
HORI-0.939
GHIX-0.938
FIAC-0.938
XPAX-0.938
NECB-0.936
ADAL-0.935
ACAB-0.935

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmunoGen Inc Correlation - Currency/Commodity

The country flag 0.27
( neutral )
The country flag -0.04
( neutral )
The country flag 0.40
( neutral )
The country flag 0.55
( weak )
The country flag -0.69
( moderate negative )
The country flag -0.71
( moderate negative )

ImmunoGen Inc Financials

Annual 2022
Revenue: $108.78M
Gross Profit: $108.61M (99.84 %)
EPS: $-0.880
Q3 2023
Revenue: $113.43M
Gross Profit: $111.27M (98.10 %)
EPS: $0.100
Q4 2023
Revenue: $83.15M
Gross Profit: $82.24M (98.91 %)
EPS: $-0.0161
Q2 2023
Revenue: $83.15M
Gross Profit: $82.24M (98.91 %)
EPS: $-0.0161

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators